Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1

Interventions

fludarabine phosphate 16Peripheral Blood Stem Cell Transplantation 14Cytarabine 12Cyclophosphamide 12Whole-Body Irradiation 10Filgrastim 9Cyclosporine 9Busulfan 9Mycophenolic Acid 8Tacrolimus 7Etoposide 7Antilymphocyte Serum 7Radiotherapy 6Methotrexate 6Granulocyte Colony-Stimulating Factor 6Cord Blood Stem Cell Transplantation 6Methylprednisolone 5Flow Cytometry 5Thiotepa 4Mitoxantrone 4Melphalan 4Idarubicin 4Decitabine 4fludarabine 3aldesleukin 3Transplantation 3Interleukin-2 3Bortezomib 3Alemtuzumab 3Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Congenital Abnormalities × Proteasome Inhibitors × Clear all
NCT02030405 2019-04-05

Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Stanford University

Phase 2 Terminated
4 enrolled 10 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡